The first domestic targeted il-36r monoclonal antibody was administered to the first subject in New Zealand
According to the official account of WeChat, Shanghai, China's Limited by Share Ltd has announced that the HB0034 project, the first recombinant IL-36R monoclonal antibody against human IL-36R, has been completed in New Zealand. The phase ia clinical study conducted in New Zealand aims to evaluate the safety, tolerance, immunogenicity and pharmacokinetics of hb0034 in healthy subjects. Huaaotai biology is a subsidiary of Huahai pharmaceutical, a listed company.
This text is a result of machine translation.
Related companies：
Briefing Mar 21, 2025 05:14 PM
· Technology
Shanghai to Launch Its First Direct Passenger Flight Route to a Central Asian Country in May
In-depth
Technology
DeepSeek | China's AI Global Breakthrough and Ecosystem Restructuring
Mar 19, 2025 01:18 PM
Briefing Oct 20, 2023 06:03 PM
· Technology
China’s OpenAI Challenger Zhipu AI Secures Over CNY 2.5 Billion to Step Further on Large-Scale Model
Briefing Sep 18, 2023 07:40 PM
· Technology
4Paradigm Initiates IPO Today and Targets HKSE on September 28
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Briefing Aug 26, 2021 06:31 PM
· Healthcare
Huahai pharmaceutical: the net profit in the first half of the year was 516 million yuan, a year-on-year decrease of 10.84%
See more
Read next
Insight
In-depth
Automotive · Analysis
Chinese Carmakers Expanding into Europe: Beware of Four Major Misconceptions
Apr 22, 2025 09:32 PM
Insight
In-depth
Consumer Staples · Analysis
Perfect Timing: Chagee Bridges the Cultural Gap in the U.S. Tea Market
Apr 22, 2025 03:29 PM
Insight
In-depth
Automotive · Analysis
Chinese Automakers Break into a €10 Billion Market in Europe
Apr 11, 2025 09:57 PM
Insight
In-depth
Automotive · Analysis
Tariff Escalation Through the Lens of Geopolitical Economy
Apr 11, 2025 12:32 PM